Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Profit After Tax: 2009-2025

Historic Profit After Tax for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Profit After Tax rose 33.31% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year decrease of 153.02%. This contributed to the annual value of -$14.2 million for FY2025, which is 10.49% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Profit After Tax is $2.0 million, which was up 109.61% from -$20.4 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Profit After Tax peaked at $4.0 million during Q1 2025, and registered a low of -$53.3 million during Q1 2022.
  • In the last 3 years, Aytu Biopharma's Profit After Tax had a median value of -$2.5 million in 2023 and averaged -$3.4 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 1,058.35% in 2023, then soared by 238.34% in 2025.
  • Over the past 5 years, Aytu Biopharma's Profit After Tax (Quarterly) stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then spiked by 109.25% to $619,000 in 2023, then rose by 27.30% to $788,000 in 2024, then soared by 33.31% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, -$20.4 million for Q2 2025, and $4.0 million during Q1 2025.